Advertisement

Topics

Vertex Receives CHMP Positive Opinion for ORKAMBI (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union

07:31 EST 10 Nov 2017 | FinanzNachrichten

- In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Uni...

Original Article: Vertex Receives CHMP Positive Opinion for ORKAMBI (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union

NEXT ARTICLE

More From BioPortfolio on "Vertex Receives CHMP Positive Opinion for ORKAMBI (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...